UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM ~~10-Q/A~~10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30,~~ December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File ~~Number:~~ Number: ~~333-234815~~000-56589

GENVOR INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada		83-2054746
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

201 S. Elliott Road, Suite 538

Chapel Hill, North Carolina 27514

(Address of principal executive offices)

(984) 261-7338

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: ~~None.~~

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Securities registered under Section 12(g) of the Act:

Common Stock, $0.001 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the ~~registrant~~registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No ☐

Indicate by check mark whether the ~~registrant~~Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the ~~registrant~~Registrant was required to submit and post such files). ☒ Yes ☒ No ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See ~~the~~ definitions of “large accelerated filer,” “accelerated ~~filer”~~filer,” “smaller reporting company” and ~~smaller reporting~~“emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

☐	Large accelerated filer	☐	Accelerated filer
☐☒
Non-accelerated filer	☒	Smaller reporting company
		☒
		Emerging growth company	☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant ishas filed a ~~shell company (as defined in Rule 12b-2~~report on and attestation to its management’s assessment of the ~~Exchange Act).~~effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐ ~~Yes ☒~~ No

AsIf securities are registered pursuant to Section 12(b) of ~~August 11,~~the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

On March 31, 2023, the ~~Company~~last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant had an undetermined value as the registrant’s common stock was not trading on any exchange, nor was it quoted for trading on the OTC Link ATS or any other over-the-counter market or alternative trading system.

~~18,667,821~~

The number of the registrant’s shares of common stock ~~outstanding.~~issued, issuable and outstanding was 20,089,786 as of February 13, 2024.

~~EXPLANATORY NOTE~~

Genvor Incorporate (the “Company”) is filing this Form 10-Q/A (“Form 10-Q/A” or this “Amendment”) to amend our Periodic Report on Form 10-Q for the period ended June 30, 2023, originally filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2023 (“Original Report”), to restate our financial statements and related footnote disclosures as of and for the nine months ended June 30, 2023 (the “Affected Period”). This Form 10-Q/A also amends certain other Items in the Original Report, as listed in “Items Amended in this Form 10-Q/A” below.

~~Restatement Background~~

The Company incorrectly recorded a liability for what it believed was an extension payment associated with its USDA CRADA research contract as of September 30, 2022. However, the Company was mistaken and there was no additional payment to extend the contract only the amount originally due which had already been recorded. The error resulted in the overstatement of the Company’s current liabilities by approximately $246,000 as of June 30, 2023.

~~Effects of Restatement~~

~~See Note 1 to the Notes to consolidated financial statements included in Part I, Item 1 of this Amendment for additional information on the restatement and the related financial statement effects.~~

~~Items Amended in this Form 10-Q/A~~

~~This Form 10-K/A presents the Original Report, amended and restated with modifications as necessary to reflect the restatements. The following items have been amended to reflect the restatement:~~

~~Part I, Item 1 – Financial Statements and Supplementary Data~~

~~Part I, Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations~~

~~In addition, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing in connection with this Form 10-Q/A.~~

GENVOR INCORPORATED

INDEX

		Page
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3.	Quantitative and Qualitative Disclosures about Market Risks	7
Item 4.	Controls and Procedures	7

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	8
Item 1A.	Risk Factors	8
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	8
Item 3.	Defaults Upon Senior Securities	89
Item 4.	Mine Safety Disclosures	89
Item 5.	Other Information	89
Item 6.	Exhibits	910

SIGNATURES		1011

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Genvor Incorporated

Index to Financial Statements

		Page

Condensed Consolidated Balance Sheets at ~~June 30,~~December 31, 2023, and September 30, ~~2022~~2023 (unaudited)		F-1

Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~June 30,~~December 31, 2023, and 2022 (unaudited)		F-2

Condensed Consolidated ~~Statement~~Statements of Changes in Stockholders’ Deficit for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022 (unaudited)		F-3

Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022 (unaudited)		F-4

Notes to Condensed Consolidated Financial Statements (unaudited)		F-5

Genvor Incorporated

Condensed Consolidated Balance Sheets

(unaudited)

June 30, September 30,
2023 2022

(as restated)

ASSETS
Current assets:
Cash $ 100 $ 296,386
Other current assets 1,500 2,000
Total current assets 1,600 298,386

Fixed assets, net 16,192 17,565

Total assets $ 17,792 $ 315,951

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Convertible notes payable $ 1,179,500 $ 1,052,000
Accounts payable and accrued expenses 133,958 270,179
Due to related party 236,333 3,846
SBA loan 48,750 48,750
USDA CRADA liability - 246,400
Total current liabilities 1,598,541 1,621,174
Non-current liabilities:
Convertible notes payable, net of discounts 179,555 89,221
Total non-current liabilities 179,555 89,221
Total liabilities 1,778,096 1,710,395

Commitments and contingencies (Note 6)

Stockholders’ deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized
Preferred stock - series A, 10 shares authorized, 9 and 9 shares issued and outstanding as of June 30, 2023 and September 30, 2022, respectively - -
Preferred stock - series B, 2,500,000 shares authorized, 2,060,536 and 0 shares issued and outstanding as of June 30, 2023 and September 30, 2022, respectively 2,061 -
Preferred stock value
Common stock, $0.001 par value, 300,000,000 shares authorized, 18,572,821 and 38,678,155 shares issued, issuable and outstanding as of June 30, 2023 and September 30, 2022, respectively 18,573 38,678
Additional paid-in capital 14,876,859 14,608,815
Accumulated deficit (16,657,797 ) (16,041,797 )
Total stockholders’ deficit (1,760,304 ) (1,394,444 )

Total liabilities and stockholders’ deficit $ 17,792 $ 315,951

	December 31,			September 30,
	2023			2023
ASSETS
Current assets:
Cash	$	207,635		$	44,354
Prepaid expenses		17,500			21,975
Other current assets		-			-
Total current assets		225,135			66,329

Fixed assets, net		15,276			15,734

Total assets	$	240,411		$	82,063

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Convertible notes payable	$	1,017,000		$	1,319,500
Accounts payable and accrued expenses		317,388			388,809
Due to related party		50,515			30,000
SBA loan		48,750			48,750
Total current liabilities		1,433,653			1,787,059
Total liabilities		1,433,653			1,787,059

Commitments and contingencies (Note 6)		-			-

Stockholders’ deficit:
Preferred stock, $0.001 par value, 20,000,000 shares authorized
Preferred stock - series A, 10 shares authorized, 6 and 9 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively		-			-
Preferred stock - series B, 2,500,000 shares authorized, 2,060,536 shares issued as of December 31, 2023 and September 30, 2023, 1,558,024 outstanding as of December 31, 2023 and September 30, 2023		2,061			2,061
Preferred stock value		2,061			2,061
Common stock, $0.001 par value, 300,000,000 shares authorized, 19,835,536 and 19,061,936 shares issued, issuable and outstanding as of December 31, 2023 and September 30, 2023, respectively		19,836			19,062
Treasury stock, 502,512 shares of series B preferred stock at December 31, 2023 and September 30, 2023		(300,000	)		(300,000	)
Additional paid-in capital		18,155,595			16,293,188
Accumulated deficit		(19,070,734	)		(17,719,307	)
Total stockholders’ deficit		(1,193,242	)		(1,704,996	)

Total liabilities and stockholders’ deficit	$	240,411		$	82,063

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-1

Genvor Incorporated

Condensed Consolidated Statements of Operations

(unaudited)

2023 2022 2023 2022
For the Three Months Ended For the Nine Months Ended
June 30, June 30,
2023 2022 2023 2022
(as restated)
Revenue $ - $ - $ - $ -

Operating expenses
Professional fees 59,762 45,170 125,424 132,928
Payroll related expenses 37,500 37,500 112,500 180,725
Research and development - - - 109,248
Stock-based compensation - 502,875 - 3,712,500
Depreciation expense 458 458 1,374 1,374
Other general and administrative expenses 51,352 59,500 178,717 163,987
Total operating expenses 149,072 645,503 418,015 4,300,762

Operating loss (149,072 ) (645,503 ) (418,015 ) (4,300,762 )

Other income (expense)
Interest expense (5,846 ) (12,240 ) (17,511 ) (73,242 )
Loss on debt settlement - - - (5,000 )
Penalties (30,000 ) (30,000 ) (90,000 ) (90,000 )
Amortization of debt discount (30,111 ) - (90,334 ) -
Total other income (expense) (65,956 ) (42,240 ) (197,844 ) (168,242 )

Net loss $ (215,029 ) $ (687,743 ) $ (615,860 ) $ (4,469,004 )

Basic and diluted net loss per common share $ (0.01 ) $ (0.02 ) $ (0.03 ) $ (0.15 )
Basic and diluted weighted average common shares outstanding 18,502,546 36,439,887 19,800,317 30,506,420

	2023			2022
	For the Three Months Ended
	December 31,
	2023			2022

Revenue	$	-		$	-

Operating expenses
Professional fees		267,586			6,804
Payroll related expenses		-			37,500
Stock-based compensation		907,100			-
Depreciation expense		458			458
Other general and administrative expenses		129,932			68,900
Total operating expenses		1,305,076			113,662

Operating loss		(1,305,076	)		(113,662	)

Other income (expense)
Interest expense		(16,351	)		(5,846	)
Penalties		(30,000	)		(30,000	)
Amortization of debt discount		-			(30,111	)
Total other income (expense), net		(46,351	)		(65,957	)

Net loss	$	(1,351,427	)	$	(179,619	)

Basic and diluted net loss per common share	$	(0.07	)	$	(0.01	)
Basic and diluted weighted average common shares outstanding		19,417,421			22,471,749

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-2

Genvor Incorporated

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

For the Three ~~and Nine~~ Months Ended ~~June 30,~~December 31, 2023 ~~and 2022~~

(unaudited)

Shares Amount Shares Amount Shares Amount Capital Deficit Total
Series A Series B Additional Accumu-
Preferred Stock Preferred Stock Common Stock Paid-in lated
Shares Amount Shares Amount Shares Amount Capital Deficit Total
Balance, September 30, 2021 - $ - - $ - 20,000,000 $ 2,000 $ - $ (64,540 ) (62,540 )
Recapilitalization / RTO impact - - - - - 18,000 8,546,798 (10,947,544 ) (2,382,746 )
Adjusted balance, beginning of period - - - - 20,000,000 20,000 8,546,798 (11,012,084 ) (2,445,286 )
Common stock issued for services - - - - 2,650,000 2,650 197,350 - 200,000
Exercise of options - - - - 1,400,000 1,400 - 1,400
Common stock issued for cash - - - - 1,475,020 1,475 736,035 737,510
Net loss for the period ended December 31, 2021 - - - - - - - (515,716 ) (515,716 )
Balance, December 31, 2021 - $ - - $ - 25,525,020 $ 25,525 $ 9,480,183 $ (11,527,800 ) $ (2,022,092 )
Common stock issued for services - - - - 6,020,000 6,020 3,003,980 - 3,010,000
Issuance of common stock for services - - - - - - - - -
Common stock issued for cash - - - - 280,000 280 139,720 - 140,000
Common stock issued for debt conversion - - - - 688,675 689 336,884 - 337,573
Payment for reverse capitalization - - - - - - (150,000 ) - (150,000 )
419 fund raising services - - - - 170,000 170 (170 ) - -
Net loss for the period ended March 31, 2022 - - - - - - - (3,265,545 ) (3,265,545 )
Balance, March 31, 2022 - $ - - $ - 32,683,695 $ 32,684 $ 12,810,597 $ (14,793,345 ) $ (1,950,064 )
Founder shares issued 1,855,888 1,856 (1,856 ) -
Common stock issued for services 505,000 505 501,995 502,500
Common stock issued for cash 25,000 25 24,975 25,000
Common stock issued for settlement 99,600 100 (100 ) -
Common stock issued to prior S-1 investors 180,400 180 48,750 48,930
Stock issued for debt conversion 1,933,972 1,934 944,224 946,158
Net loss for the period ended June 30, 2022 - - - - - - - (687,743 ) (687,743 )
Balance, June 30, 2022 - $ - - $ - 37,283,555 $ 37,284 $ 14,328,585 $ (15,481,088 ) $ (1,115,219 )

Balance, September 30, 2022 - $ - - $ - 38,678,155 $ 38,678 $ 14,608,815 $ (16,041,937 ) $ (1,394,444 )
Conversion of common stock into Series B preferred stock - - 2,060,536 2,061 (20,605,334 ) (20,605 ) 18,544 - -
Sale of common stock - - - - 300,000 300 149,700 - 150,000
Net loss for the period ended December 31, 2022 - - - - - - - (179,539 ) (179,539 )
Balance, December 31, 2022 - $ - 2,060,536 $ 2,061 18,372,821 $ 18,373 $ 14,777,059 $ (16,221,476 ) $ (1,423,983 )
Sale of common stock - - - - 50,000 50 12,450 - 12,500
Net loss for the period ended March 31, 2023 - - - - - - - (221,212 ) (221,212 )
Balance, March 31, 2023 - $ - 2,060,536 $ 2,061 18,422,821 $ 18,423 $ 14,789,509 $ (16,442,688 ) $ (1,632,695 )
Sale of common stock - - - - 125,000 125 74,875 - 75,000
Conversion of note payable into common stock 25,000 25 12,475 - 12,500
Net loss for the period ended June 30, 2023 - - - - - - - (215,029 ) (215,029 )
Balance, June 30, 2023 - $ - 2,060,536 $ 2,061 $ 18,572,821 $ 18,573 $ 14,876,859 $ (16,657,797 ) $ (1,760,304 )

	Shares		Amount		Shares		Amount		Shares			Amount			Stock			Capital			Deficit			Total
	Series A				Series B													Additional			Accumu-
	Preferred Stock				Preferred Stock				Common Stock						Treasury			Paid-in			lated
	Shares		Amount		Shares		Amount		Shares			Amount			Stock			Capital			Deficit			Total
Balance, September 30, 2022		9	$	-		-	$	-		38,678,155		$	38,678		$	-		$	14,608,815		$	(16,041,937	)		(1,394,444	)
Conversion of common stock into series B preferred stock		-		-		2,060,536		2,061		(20,605,334	)		(20,605	)		-			18,544			-			-
Sale of common stock		-		-		-		-		300,000			300			-			149,700			-			150,000
Net loss for the period ended December 31, 2022		-		-		-		-		-			-			-			-			(179,619	)		(179,619	)
Balance, December 31, 2022		9	$	-		2,060,536	$	2,061		18,372,821		$	18,373		$	-		$	14,777,059		$	(16,221,556	)	$	(1,424,063	)

Balance, September 30, 2023		6	$	-		1,558,024	$	2,061		19,061,936		$	19,062		$	(300,000	)	$	16,293,188		$	(17,719,307	)	$	(1,704,996	)
Balance		6	$	-		1,558,024	$	2,061		19,061,936		$	19,062		$	(300,000	)	$	16,293,188		$	(17,719,307	)	$	(1,704,996	)
Sale of common stock		-		-		-		-		623,600			624			-			577,976			-			578,600
Issuance of common stock erroneously omitted from prior year		-		-		-		-		50,000			50			-			(50	)		-			-
Double issuance of common stock		-		-		-		-		60,000			60			-			(60	)		-			-
Issuance of warrants for services		-		-		-		-		-			-			-			907,100			-			907,100
Issuance of warrants for conversion of note payable		-		-		-		-		-			-			-			329,418			-			329,418
Issuance of common stock for conversion of note payable		-		-		-		-		40,000			40			-			48,023			-			48,023
Net loss for the period ended December 31, 2023		-		-		-		-		-			-			-			-			(1,351,427	)		(1,351,427	)
Balance, December 31, 2023		6	$	-		1,558,024	$	2,061		19,835,536		$	19,836		$	(300,000	)	$	18,155,595		$	(19,070,734	)	$	(1,193,242	)
Balance		6	$	-		1,558,024	$	2,061		19,835,536		$	19,836		$	(300,000	)	$	18,155,595		$	(19,070,734	)	$	(1,193,242	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3

Genvor Incorporated

Condensed Consolidated Statements of Cash Flow

For the ~~Nine~~Three Months Ended ~~June 30,~~December 31,

(unaudited)

	2023			2022
	(as restated)						2023			2022
Cash flows from operating activities:
Net loss	$	(615,860	)	$	(4,469,004	)	$	(1,351,427	)	$	(179,619	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		1,374			1,374			458			458
Stock-based compensation		-			3,712,500			907,100			-
Late fee capitalized into notes payable		90,000			90,000			30,000			-
Loss on debt settlement		-			5,000
Common stock issued for interest expense		-			2,500
Amortization of debt discount		90,334			10,911
Beneficial conversion feature								-			30,111
Changes in assets and liabilities:
Prepaid expenses		-			3,393			4,475			-
Other current assets		500			-			-			(13,398	)
Accounts payable and accrued expenses		96,266			(27,076	)		(26,440	)		(1,075	)
Due to related party								20,515			-
USDA CRADA liability		(246,400	)		2,800			-			(246,400	)
Net cash used in operating activities		(583,786	)		(667,602	)		(415,319	)		(409,923	)

Cash flows from financing activities:
Proceeds from notes payable		50,000			300,000			-			50,000
Repayments of related party payable		-			(4,330	)
Proceeds from sale of common stock		237,500			735,005			578,600			150,000
Net cash provided by financing activities		287,500			1,030,675			578,600			200,000

Net increase in cash		(296,286	)		363,073
Net increase (decrease) in cash								163,281			(209,923	)

Cash at beginning of period		296,386			72,315			44,354			296,386

Cash at end of period	$	100		$	435,388		$	207,635		$	86,463

Cash paid for interest	$	-		$	-		$	-		$	-
Cash paid for taxes	$	-		$	-		$	-		$	-

Non-cash investing and financing activities:
Conversion of notes payable into warrants							$	300,000		$	-
Conversion of note payable into common stock	$	12,500		$	-		$	48,063		$	-
Principal and interest settled through common stock issuance	$	-		$	1,135,946
Accrued payroll settled through common stock issuance	$	-		$	125,750
Right of use, lease asset and liability	$	-		$	13,480
Prepaid costs for reverse capitalization recognized in additional paid-in capital	$	-		$	150,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4

GENVOR INCORPORATED

Notes to Condensed Consolidated Financial Statements

~~June 30,~~December 31, 2023

(unaudited)

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

Company Background

On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.

During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, ~~2018 (“inception”).~~2018. The condensed consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.

Nature of Operations

The Company’s business plan is ~~developing~~that Genvor will be continuing its research and development addressing plant-based defense technology ~~designed~~which then can be commercialized to help farmers ~~achieve global~~and growers globally to overcome potentially catastrophic losses resulting from plant disease, toxins, bacteria, and fungi that destroy their crops. These solutions can result in greater crop yields and economic savings, which can assist in overcoming world-wide food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.scarcity.

Basis of Presentation

The accompanying unaudited condensed consolidated financial information as of and for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022 has been prepared in accordance with accounting principles generally accepted in the United States (“U.S. ~~GAAP~~GAAP”) for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial position at such date and the operating results and cash flows for such periods. Operating results for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with ~~generally accepted accounting principles~~U.S. GAAP have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission, or the SEC. These unaudited financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended September 30, ~~2022,~~2023, as filed with the SEC.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The condensed consolidated financial statements included herein, presented in accordance with ~~United States generally accepted accounting principles (“GAAP”)~~U.S. GAAP and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

F-5

Liquidity and Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At ~~June 30,~~December 31, 2023, the Company had an accumulated deficit of $~~16,657,797~~19,070,734. For the ~~nine~~three months ended ~~June 30,~~December 31, 2023, the Company recognized a net loss of $~~615,860~~1,351,427 and had net cash used in operating activities of $~~583,786~~415,319, with no revenues earned, and ~~a lack of~~limited operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

While the Company is ~~attempting to generate revenues,~~currently developing its products and technologies, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate ~~revenues.~~cash flows from financing activities or operating activities. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

~~Restatement of Previously Issued Financial Statements~~

The Company has restated the accompanying consolidated financial statements for the September 30, 2022 and the three and nine months ended June 30, 2023, along with certain notes to such restated financial statements. The adjustments recorded were related to the correction of an error identified by management. The nature and impact of this adjustment on the Company’s previously issued financial statements is summarized as follows and the effects by impacted line items are detailed in the tables below. Impacted amounts and associated disclosures are restated within the accompanying notes to the financial statements.

~~The following tables summarize the effect of the restatement on each financial statement line items as of and for the nine months ended June 30, 2023.~~

~~SCHEDULE OF RESTATEMENT ON FINANCIAL STATEMENT~~

As previously As
Reported Adjustments Restated
Consolidated Balance Sheets as of June 30, 2023
USA CRADA liability $ 246,400 $ (246,400 ) $ -
Total current liabilities $ 1,844,941 $ (246,400 ) $ 1,598,541
Total liabilities $ 2,024,496 $ (246,400 ) $ 1,778,096
Accumulated deficit $ (16,904,197 ) $ 246,400 $ (16,657,797 )
Total stockholders’ deficit $ (2,006,704 ) $ 246,400 $ (1,760,304 )
Total liabilities and stockholders’ deficit $ 17,792 $ - $ 17,792
Consolidated Statement of Operations for the nine months ended June 30, 2023
Other general and administrative expenses $ 178,637 $ 80 $ 178,717
Total operating expenses $ 417,935 $ 80 $ 418,015
Operating loss $ (417,935 ) $ (80 ) $ (418,015 )
Net loss $ (615,780 ) $ (80 ) $ (615,860 )
Basic and diluted net loss per common share $ (0.03 ) $ (0.00 ) $ (0.03 )
Basic and diluted weighted average common shares outstanding $ 19,800,317 $ 19,800,317
Consolidated Statement of Cash flows for the nine months ended June 30, 2023
Net loss $ (615,780 ) $ (80 ) $ (615,860 )
USA CRADA liability $ - $ (246,400 ) $ (246,400 )
Accounts payable and accrued expenses $ (150,214 ) $ 246,480 $ 96,266
Net cash used in operating activities $ (583,786 ) $ - $ (583,786 )
Consolidated Statements of Changes in Stockholders’ Deficit for the nine months ended June 30, 2023
Net loss $ (615,780 ) $ (80 ) $ (615,860 )
Accumulated deficit $ (16,904,197 ) $ 246,400 $ (16,657,797 )

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with ~~generally accepted accounting principles~~U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent ~~assets and~~ liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Flow Reporting

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

Cash ~~and Cash Equivalents~~

Cash is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances exceed applicable Federal Deposit Insurance Corporation (“FDIC”) insurance amounts of $250,000. From time to time, the Company has certain cash balances, including restricted cash, that may exceed insured limits. The Company ~~considers all highly liquid debt instruments and other short-term investments with a maturity of three months or less, when purchased, to be cash equivalents. There were~~ no ~~cash equivalents as of June 30, 2023, and September 30, 2022.~~utilizes large banking institutions that are reputable, therefore mitigating the risks.

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At ~~June 30,~~December 31, 2023, ~~and September 30, 2022, $~~0 ~~and $46,386, respectively,~~ the Company’s cash balances were not in excess of federally insured limits.

F-6

Fixed Assets

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven ~~years~~.years. Expenditures for minor enhancements and maintenance are expensed as incurred.

~~Stock-Based Compensation~~

~~The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718,~~ ~~Compensation – Stock Compensation, and Certain Redeemable Financial Instruments~~. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

~~F-7~~

Fair Value of Financial Instruments

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under U.S. GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

The hierarchy consists of three levels

	●	Level one — Quoted market prices in active markets for identical assets or liabilities;
	●	Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	●	Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

Financial Instruments

The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, Financial Instruments. The carrying amount of these financial instruments, as reflected in the accompanying condensed consolidated balance ~~sheet,~~sheets approximates fair value.

Long-lived Assets

The Company’s long-lived assets and other assets (consisting of furniture, equipment, and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. ~~Recoverability~~The recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such an asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management, which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.

Research and Development

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of ~~the~~ plant-based defense technology products. For the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022, the Company had $0 and $~~109,248~~0 in research and development expenses, respectively.

F-7

Patents

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360,

Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

~~F-8~~

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of ~~June 30,~~December 31, 2023. Interest and penalties, inif any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the ~~nine~~three months ended ~~June 30,~~December 31, 2023.

Stock-Based Compensation

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

The Company measures compensation cost for all employee stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method.

Loss Per Share of Common Stock

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for the periods presented. The Company had total potential additional dilutive securities outstanding at ~~June 30,~~December 31, 2023 and ~~September 30,~~ 2022 of $~~22,065,343~~500,000 and $~~1,460,009~~665,000, respectively.

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently ~~utilizing~~evaluating the ~~guidance as applicable. There have been no material impacts~~impact of ASU 2020-06 on ~~the Company’s financials.~~its condensed consolidated financial statements.

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

F-8

NOTE 3 – BORROWINGS

Commercial Loan

On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program ~~(PPP)~~(“PPP”) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida ~~(NBFL)~~(“NBFL”) (a related party) and the CEO.

~~F-9~~

Payable for Patent

Notes Payable

From time to time, the Company’s subsidiary, Old Genvor, ~~Inc., enters~~entered into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.

SCHEDULE OF CONVERTIBLE NOTES PAYABLE

Balance
Convertible
Interest Loan into
Noteholder Origination Maturity Rate Balance Shares (c)
Noteholder A (a) 2019 12/31/2021 0 % $ 217,000 N/A
Noteholder B (a) 3/19/2019 4/29/2019 0 % 540,000 N/A
Noteholder C (a) 3/1/2019 2/29/2020 18 % 32,500 N/A
Noteholder D (d) 4/29/2019 unspecified 0 % 300,000 30,000
Noteholder E (a) 8/1/2019 8/31/2019 0 % 37,500 N/A
Noteholder F (a)(b) 2/27/2020 4/30/2020 0 % 2,500 5,000
Noteholder H 6/27/2022 6/27/2024 5 % 300,000 1,000,000
Noteholder I (c) 10/26/2022 12/31/2023 3 % 50,000 400,000
1,479,500 1,435,000
(d) Debt discount (120,445 )
$ 1,359,055

										Balance
										Convertible
					Interest			Loan		into
Noteholder	Origination		Maturity		Rate			Balance		Shares (c)
Brent Lilienthal (a) (b)		2019		12/31/2021		0	%	$	217,000		N/A
Mel Wentz (a) (b)		3/19/2019		4/29/2019		0	%		600,000		N/A
Barkley Capital LLC		9/13/2023		3/13/2024		10	%		200,000		134,000
								$	1,017,000		134,000

(a)	Past due at ~~June 30,~~December 31, 2023
(b)	~~Note is payable in a combination of $2,500~~ ~~to $6,000~~ ~~in cash and~~ ~~5,000~~ to ~~15,000~~ ~~share of common stock~~In dispute
(c)	Convertible into common stock of the subsidiary, Old Genvor ~~Inc.~~

The notes do not have default provisions except ~~Noteholder B~~for Mel Wentz receives a default penalty of $10,000 each month the note goes unpaid.

The Company is currently disputing amounts claimed to be owed to two noteholders, Brent Lilienthal, and Mel Wentz, under state usury laws (See Note 6).

On September 13, 2023, the Company entered into a convertible promissory note with Barkley Capital LLC for $200,000. The note matures on March 13, 2024, and bear interest of 10%. The note is convertible into 134,000 shares of common stock at a value of $1.50 per share.

On November 11, 2023, John Hare converted the $300,000 note payable into 300,000 warrants with an exercise price of $0.001 (see Note 4).

On December 15, 2023, R. Kirk Huntsman converted the $32,500 note payable into 40,000 shares of common stock.

During the year ended September 30, 2023, $76,325 principal was converted into 122,115 common stock shares of the Company. Additionally, $350,000 principal and $4,114 interest were converted into 1,400,000 warrants for common stock of the Company.

Interest expense totaled $~~17,511~~41,851 and $~~73,242~~35,846, respectively, for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022, including default penalties. Late fees totaled $~~90,000~~30,000 and $~~90,000~~30,000, respectively, for the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022. These late fees are in dispute and part of (a) and (b) above.

F-9

NOTE 4 – STOCKHOLDERS’ DEFICIT

Preferred Stock

The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value.

Series A Preferred Stock

On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).

~~As of June 30, 2023, and September 30, 2022, there were~~ 9 ~~and~~ 9 ~~shares of Series A preferred stock issued and outstanding, respectively.~~ The preferred stock was issued on August 16, 2022, as follows: Bradley White (former Chief Executive ~~Officer and Director)~~Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

On September 28, 2023, as part of the Settlement Agreement with Bradley White (see Notes 6 and 7), Mr. White returned to the Company for cancellation of 3 shares of Series A preferred stock.

As of December 31, 2023, and September 30, 2023, there were 6 and 9 shares of Series A preferred stock issued and outstanding, respectively.

Series B Preferred Stock

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”). The designation authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See Note 10.

~~F-10~~

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

SCHEDULE OF CONVERTED SHARES OF COMMON STOCK

Name	Common Shares Exchanged		Series B Issued		Common Shares Exchanged		Series B Issued
Jaynes Investment LLC(a)		2,000,000		200,000		2,000,000		200,000
ACT Holdings LLC(a)		7,312,612		731,262		7,312,612		731,262
LASB Family Trust(a)		3,800,112		380,012		3,800,112		380,012
Jesse Michael Jaynes(a)		4,767,611		476,762		4,767,611		476,762
Bradley White (a)		1,225,000		122,500		1,225,000		122,500
PJ Advisory Group		1,500,000		150,000		1,500,000		150,000
Total		20,605,334		2,060,536		20,605,334		2,060,536

(a)

Related ~~party~~parties

The conversion of the common stock into ~~the~~ Series B was valued at par, respectively, offset to additional paid-in capital. ~~The~~ Series B is convertible into common stock into the original amount of common stock converted therefore there is no change in the amount of common stock outstanding on a fully diluted basis.

F-10

On September 28, 2023, as part of the Settlement Agreement with Bradley White (see Notes 6 and 7), Mr. White returned to the Company for cancellation of 502,512 shares of Series B preferred stock.

As of ~~June 30,~~December 31, 2023, and September 30, ~~2022,~~2023, there were ~~2,060,536~~1,558,024 and 01,558,024 shares of Series B preferred stock issued and outstanding, respectively.

Common Stock

The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.

On April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $0.50, accordingly the shares were valued at $285, and the note was written off since NBFL has since dissolved.

In connection with the Merger (see ~~Note 1)~~Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”

During July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the note receivable held in NBFL. Since NBFL had minimal assets and was dissolved during the year ended December 31, 2019, the note receivable was immediately written-off. Based on the latest SPA price per share, the stock was valued at $1.00 per share, or $99,600.

On September 8, 2022, the Company issued 100,000 shares of common stock to a prior Nexion contractor. This was regarding a claim against the predecessor management and the Company opted as a settlement to issue the common stock.

Shares Issued for Services

During the year ended September 30, 2023, and the nine months ended September 30, 2022, the Company issued 0 and 751,500 shares of common stock, respectively, for business advisory services received, valued at $0 and $325,750, respectively.

On February 18, 2022, the Company issued 20,000 shares of common stock, valued at $10,000 (based on the latest third-party sale of common stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $2,500 (based on the latest third-party sale of common stock), recorded in interest expense in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2022.

On March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued valued at $3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the accompanying condensed consolidated statement of operations.

During April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $2,500 and recorded in stock compensation in the accompanying consolidated statement of operations.

On May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common stock, this resulted in $500,000 stock-based compensation.

On September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.

F-11

Stock Issued for Cash

From October through December 2021, the Company entered into fourteen stock purchase agreements (“SPA”) for the issuance of a total of 1,475,020 shares of common stock at prices ranging from $0.40-$0.50. The proceeds received under these SPAs totaled $570,005.

During January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $0.50. The proceeds received under these SPAs totaled $140,000.

On May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $25,000, or $1.00 per share.

During July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.

During July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA.

On November 17, 2022, the Company issued 300,000 shares of common stock to an investor for $150,000.

On May 3, 2023, the Company issued 100,000 shares of common stock to an investor for $50,000.

On May 12, 2023, the Company issued 15,000 shares of common stock to an investor for $15,000.

On May 29, 2023, the Company issued 10,000 shares of common stock to an investor for $10,000.

On July 12, 2023, the Company issued 20,000 shares of common stock to an investor for $10,000.

On July 13, 2023, the Company issued 20,000 shares of common stock to an investor for $10,000.

On July 14, 2023, the Company issued 50,000 shares of common stock to an investor for $25,000.

On July 17, 2023, the Company issued 25,000 shares of common stock to an investor for $10,000.

On August 25, 2023, the Company issued 50,000 shares of common stock to an investor for $25,000.

On September 16, 2023, the Company issued 75,000 shares of common stock for the settlement of a debt and accrued interest for $25,000.

On September 19, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

On November 1, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

On November 1, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

On November 6, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

On November 8, 2023, the Company issued 25,000 shares of common stock to an investor for $25,000.

On November 8, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

On November 10, 2023, the Company issued 25,600 shares of common stock to an investor for $25,600.

F-12

On November 13, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

On November 14, 2023, the Company issued 25,000 shares of common stock to an investor for $25,000.

On December 8, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

On December 11, 2023, the Company issued 10,000 shares of common stock to an investor for $10,000.

On December 13, 2023, the Company issued 100,000 shares of common stock to an investor for $100,000.

On December 14, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

On December 20, 2023, the Company issued 53,000 shares of common stock to an investor for $53,000.

On December 26, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

Other Stock Issuances

On June 14, 2023, the Company issued 25,000 shares of common stock related to the conversion of a note payable for $12,500.

On July 1, 2023, the Company issued 29,665 shares of common stock related to the conversion of a note payable and accrued interest for $14,833.

On October 16, 2023, the Company issued 50,000 shares of common stock related to a sale of common stock in the prior year for $12,500.

On October 19, 2023, the Company issued 60,000 shares of common stock, which were a double issuance.

On December 15, 2023, the Company issued 40,000 shares of common stock related to the conversion of a note payable for $32,500.

Stock Options and Warrants

During the year ended September 30, 2023, the Company issued 2,362,900 warrants for common stock of the Company. The issuance was for the following:

	●	Services - 162,900 warrants for common stock with an exercise price of $0.001, valued at $142,900
	●	Services by related party – 600,000 warrants for common stock with an exercise price of $0.001, valued at $600,000
	●	Settlement of debt – 200,000 warrants for common stock with an exercise price of $0.001, valued at $200,000
	●	Conversion of notes payable and accrued interest – 1,400,000 warrants for common stock with an exercise price of $0.001, valued at $359,414

During the three months ended December 31, 2023, the Company issued 1,192,800 warrants for common stock of the Company. The issuance was for the following:

	●	Services – 392,800 warrants for common stock with an exercise price of $0.001, valued at $392,800
	●	Services by a related party – 500,000 warrants for common stock with an exercise price of $0.001, valued at $500,000
	●	Conversion of notes payable – 300,000 warrants for common stock with an exercise price of $0.001, valued at $343,718 (see Note 3)

NOTE 5 – FEDERAL INCOME TAX

~~As of June 30,~~No provision for federal, state or foreign income taxes has been recorded for the three months ended December 31, 2023, and ~~September 30,~~2022. The Company has incurred net operating losses for all of the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying condensed financial statements due to uncertainty around utilizing these tax attributes within their respective carryforward periods. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future. The Company’s policy is to recognize interest expense and penalties related to income tax matters as income tax expense. For the three months ended December 31, 2023, and 2022, the Company has ~~net operating loss carry forwards of $2,696,890~~ ~~and $2,572,885, respectively, which may be available~~not recognized any interest or penalties related to ~~reduce future years’ taxable~~ income through 2043. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.taxes.

~~F-11~~F-13

~~The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of~~ 21~~% to loss before taxes for fiscal year 2023 and 2022), as follows:~~

~~SCHEDULE OF LOSS BEFORE TAXES~~

June 30, September 30,
2023 2022
Tax benefit at the statutory rate $ (110,344 ) $ (204,559 )
State income taxes, net of federal income tax benefit (13,662 ) (25,326 )
Change in valuation allowance 124,006 229,885
Total $ - $ -

~~The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.~~

~~The tax years 2023 and 2022 remain open for examination by federal agencies and other jurisdictions in which it operates.~~

~~The tax effect of significant components of the Company’s deferred tax assets and liabilities at June 30, 2023, and September 30, 2022, are as follows:~~

~~SCHEDULE OF DEFERRED TAX ASSETS~~

June 30, September 30,
2023 2022
Net operating loss carryforward $ 2,696,890 $ 2,572,885
Total gross deferred tax assets 2,696,890 2,572,885
Less: Deferred tax asset valuation allowance (2,696,890 ) (2,572,885 )
Total net deferred taxes $ - $ -

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $~~2,696,890~~ ~~and $2,572,885~~ ~~as of June 30, 2023, and September 30, 2022, respectively.~~

NOTE 6 – COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of ~~operations.~~operations except as noted.

The Company is currently disputing amounts claimed to be owed to two noteholders, Brent Lilienthal, and Mel Wentz, under state usury laws (see Note 3).

Subscription Agreement and Cash Held in Escrow

On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at ~~June~~September 30, 2023 and ~~September 30,~~ 2022, totaled $19,705.

Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.

Consulting Agreements

~~During the nine months ended June 30,~~On October 5, 2023, ~~the Company paid the Company’s former CEO, Bradley White, $32,500~~ ~~pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000~~ which increases based on certain capital raise thresholds. On June 20, 2023, Mr. White was terminated as an officer of the Company. At June 30, 2023 and September 30, 2022, accrued payroll owed to the former CEO totaled $~~228,213~~ ~~and $188,484, respectively, as presented in the accompanying consolidated balance sheets.~~

~~On July 24, 2020,~~ the Company entered into ~~a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation~~an Interim CEO & Executive Consultant Agreement (the “Executive Consulting Agreement”) with Judith S. Miller, pursuant to which Judith S. Miller would serve as the ~~agreement was~~Company’s Interim CEO, and with the Executive Consulting Agreement intended to be considered effective as of June 20, 2023, the date of Ms. Miller’s original appointment as Interim CEO of the Company. Under the Executive Consulting Agreement, which can be terminated at any time with or without cause by the Company and upon 30 days’ advance written notice by Ms. Miller, Ms. Miller will act as the Interim CEO of the Company and, among other management duties, assist the Company in recruiting a full-time CEO and/or agricultural biotechnology management professional. Following the appointment of a full-time CEO, Ms. Miller will be retained as an executive consultant for a period of 6 months thereafter. For the three months ended December 31, 2023, Ms. Miller earned $~~20,000~~60,000 ~~monthly.~~.

~~F-12~~

Office Lease

The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its condensed consolidated balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. The lease was terminated in July 2023. During the ~~nine~~three months ended ~~June 30,~~December 31, 2023, and 2022, we incurred $~~10,187~~0 and $~~20,607~~8,430, respectively, in office rental ~~expense.~~expenses.

Research and Development Agreement

During September 2020, the Company assumed a Cooperative Research ~~And~~and Development Agreement ~~(CRADA)~~(“CRADA”) with the United States Department of Agriculture ~~(USDA)~~(“USDA”), Agricultural Research Service ~~(ARS)~~(“ARS”). Under this agreement, the Company committed to funding the remaining amount due.

Settlement Agreement

On September 28, 2023, the Company entered into a Settlement Agreement with Bradley White, former CEO and director of the Company, who was terminated on June 20, 2023. As part of ~~June 30, 2023, and September 30, 2022,~~the Settlement Agreement, Mr. White was to receive a total settlement of $~~246,400~~ ~~and $246,400~~300,000, ~~respectively, remained outstanding~~payable in tranches of $50,000, beginning on September 28, 2023, or within seven days, and ~~is presented in~~each subsequent payment on the ~~accompanying consolidated balance sheets as USDA CRADA liability.~~monthly anniversary of the Settlement Agreement execution. In exchange for the settlement, Mr. White returned to the Company for cancellation of the following: 3 shares of Series A preferred stock and 502,512 shares of Series B preferred stock. See Notes 4 and 7.

F-14

NOTE 7 – RELATED PARTY TRANSACTIONS

Consulting Agreement

On October 5, 2023, the Company entered into an Interim CEO & Executive Consultant Agreement (the “Executive Consulting Agreement”) with Judith S. Miller, pursuant to which Judith S. Miller would serve as the Company’s Interim CEO, and with the Executive Consulting Agreement intended to be considered effective as of June 20, 2023, the date of Ms. Miller’s original appointment as Interim CEO of the Company. Under the Executive Consulting Agreement, which can be terminated at any time with or without cause by the Company and upon 30 days’ advance written notice by Ms. Miller, Ms. Miller will act as the Interim CEO of the Company and, among other management duties, assist the Company in recruiting a full-time CEO and/or agricultural biotechnology management professional. Following the appointment of a full-time CEO, Ms. Miller will be retained as an executive consultant for a period of 6 months thereafter. For the three months ended December 31, 2023, Ms. Miller earned $60,000.

For the three months ended December 31, 2023, Ms. Miller was owed $46,669 in accrued compensation and for unreimbursed expenses.

Share Issuances to the Board of Directors

The Company issued Series A preferred stock on August 16, 2022, as follows: Bradley White (former Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.

SCHEDULE OF RELATED PARTIES CONVERTED SHARES OF COMMON STOCK

Name	Common Shares Exchanged		Series B Issued
Jaynes Investment LLC (a)		2,000,000		200,000
ACT Holdings LLC (a)		7,312,612		731,262
LASB Family Trust (a)		3,800,112		380,012
Jesse Michael Jaynes (a)		4,767,611		476,762
Bradley White (a)		1,225,000		122,500
PJ Advisory Group		1,500,000		150,000
Total		20,605,334		2,060,536

(a)	Related parties

On September 28, 2023, as part of the Settlement Agreement, Bradley White returned for cancellation 3 shares of Series A preferred stock and 502,512 shares of Series B preferred stock.

Receivables from Related Parties and Share Issuances to Related Parties

During 2018, Robert Bubeck, former CEO, paid $3,846 of expenses on behalf of the Company. The amount due to related party at December 31, 2023 and September 30, 2023, is $3,846 and is due on demand and non-interest bearing.

On December 30, 2023, the Company issued Robert Bubeck 50,000 warrants for common stock.

F-15

Settlement Agreement

On September 28, 2023, the Company entered into a Settlement Agreement with Bradley White, former CEO and director of the Company, who was terminated on June 20, 2023. As part of the Settlement Agreement, Mr. White was to receive a total settlement of $300,000, payable in tranches of $50,000, beginning on September 28, 2023, or within seven days and each subsequent payment on the anniversary date of the Settlement Agreement. In exchange for the settlement, Mr. White returned to the Company for cancellation of the following: 3 shares of Series A preferred stock and 502,512 shares of Series B preferred stock. See Notes 4 and 6.

NOTE 8 – MERGER WITH OLD GENVOR

On May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest of the combined company.

In the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total of 35,261,871 shares of Company common stock issued to Old Genvor’s pre-merger stockholders). Pursuant to the original Acquisition agreement and Merger, the Company’s founding shareholders retained 5% of the Company’s outstanding shares of common stock, or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company’s common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company’s common stock to the founding shareholders to ensure that in the aggregate they maintain their 5% ownership of the Company’s outstanding common stock.

Pursuant to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose acquisition company (“SPAC”) with no assets and only expenses related to maintaining its public shell company status, and Old Genvor has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to affect the recapitalization were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity of the Company, with a balancing adjustment through the additional paid-in capital account.

During the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $140,000 and $10,000, respectively, in anticipation of closing the Acquisition. The total $150,000 was recognized in additional paid-in capital as of the date of the Merger.

NOTE 9 – INTELLECTUAL PROPERTIES

The Company was granted a patent (#11083775) on August 10, 2021, by the United States Patent and Trademark Office. The patent was assigned by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.

NOTE 810 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the condensed consolidated balance sheet through the date of this filing and determined there were no events to disclose except the following.

F-16

On ~~July 12, 2023,~~January 5, 2024, the Company ~~sold~~ issued 6,250 shares on common stock to MZ Group, the Company’s investor relations firm. The Company is obligated to issue $25,000 ~~shares~~worth of common stock, ~~for~~each on January 5, 2024, February 5, 2024, March 5, 2024, April 5, 2024, and May 5, 2024, based on the closing price of the common stock that day. On January 5, 2024, the common stock was $~~10,000~~ ~~to an investor at a value of $0.40~~4.00 per share.

On ~~July 13, 2023,~~January 8, 2024, the Company ~~sold~~issued ~~20,000~~8,000 shares of common stock for $~~10,000~~8,000 ~~to an investor at a value of $0.50~~ ~~per share.~~.

On ~~July 14, 2023,~~January 16, 2024, the Company ~~sold~~issued ~~50,000~~25,000 shares of common stock for services to a consultant. The shares were valued at $25,000.

On January 16, 2024, the Company issued 115,000 shares of common stock for $~~25,000~~115,000 ~~to an investor at a value of $0.50~~ ~~per share.~~.

On ~~August 4,~~January 16, 2024, the Company issued 25,000 shares of common stock to Ms. Miller in conjunction with her employment agreement. The shares were valued at $25,000.

On January 17, 2024, the Company issued 100,000 warrants for common stock to Ms. Miller for a contractual milestone. The warrants were valued at $100,000.

On January 17, 2024, Ms. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors, as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company. Pursuant to the Miller Employment Agreement, which supersedes Ms. Miller’s prior Executive Consulting Agreement with the Company dated June 20, 2023, Ms. Miller will act as Chief Business Officer and Interim Chief Financial Officer of the Company until the agreement is terminated in accordance with its terms, and Ms. Miller will be compensated as follows: (i) Ms. Miller will receive a base salary of $180,000 per year; (ii) Ms. Miller will be issued 25,000 shares of Company common stock per month for a period of one year; (iii) Ms. Miller will receive an additional equity award of 250,000 shares of Company common stock upon the Company receiving the results of the scientific studies conducted by Southern Gardens/US Sugar for further use by the Company; (iv) Ms. Miller will receive an additional equity award of 50,000 shares of Company common stock upon the Company raising each tranche $1,000,000 up to an aggregate of $10,000,000; (v) Ms. Miller will receive an additional equity award of 50,000 shares of Company common stock upon the Company raising $2,500,000; (vi) Ms. Miller will receive an additional equity award of 100,000 shares of Company common stock upon the Company raising $6,000,000, and (vii) Ms. Miller will receive an additional equity award of 100,000 shares of Company common stock upon the Company raising $10,000,000.

On January 17, 2024, the Company executed ~~into~~an advisor agreement with Dr. Jesse Jaynes, a ~~promissory note with Jason Adams~~director of the Company (the “Jaynes Advisor Agreement”). Dr. Jaynes will be compensated as follows: (i) Dr. Jaynes will be paid a $50,000 signing bonus; (ii) Dr. Jaynes will be paid $5,000 per month; (iii) Dr. Jaynes will be paid $100,000 and 25,000 shares of Company common stock upon the completion of formulation and production of a peptide topical spray (biological fungicide) that is effective in its utilization of AMPs treating plant disease, for $~~15,000~~.

On any of the identified spectrums of crops that are targeted by the Company; (iv) Dr. Jaynes will be paid $100,000 and 25,000 shares of Company common stock upon the receipt of regulatory approval from any of those federal agencies required by United States, such as the United States Environmental Protection Agency (the EPA), the United States Department of Agriculture (the USDA), and/or ~~about August 4, 2023,~~the United States Food and Drug Administration (the FDA), for the commercialization of the topical spray; (v) Dr. Jaynes will be paid $100,000 and 25,000 shares of Company common stock upon the commercial sale of a minimum of $10,000,000 of the topical spray; and (vi) Dr. Jaynes will be paid $100,000 and 25,000 shares of Company common stock upon the receipt of regulatory approval from any of those federal agencies required by the United States, such as the EPA, USDA, and/or the FDA, for the commercialization of the first seed trait based upon the Company’s ~~former~~patents and targeted spectrums of crops.

F-17

On January 17, 2024, the Company executed an advisor agreement with Dr. Clayton Yates, a director of the Company (the “Yates Advisor Agreement”). Dr. Yates will be compensated as follows: (i) Dr. Yates will be paid a $50,000 signing bonus; (ii) Dr. Yates will be paid $5,000 per month; (iii) Dr. Yates will be paid $100,000 and 25,000 shares of Company common stock upon the completion of formulation and production of a peptide topical spray (biological fungicide) that is effective in its utilization of AMPs treating plant disease, for any of the identified spectrums of crops that are targeted by the Company; (iv) Dr. Yates will be paid $100,000 and 25,000 shares of Company common stock upon the receipt of regulatory approval from any of those federal agencies required by United States, such as the United States Environmental Protection Agency (the EPA), the United States Department of Agriculture (the USDA), and/or the United States Food and Drug Administration (the FDA), for the commercialization of the topical spray; (v) Dr. Yates will be paid $100,000 and 25,000 shares of Company common stock upon the commercial sale of a minimum of $10,000,000 of the topical spray; and (vi) Dr. Yates will be paid $100,000 and 25,000 shares of Company common stock upon the receipt of regulatory approval from any of those federal agencies required by the United States, such as the EPA, USDA, and/or the FDA, for the commercialization of the first seed trait based upon the Company’s patents and targeted spectrums of crops.

On January 17, 2024, the Company was appointed as Chief Executive Officer ~~Bradley White, and LASB Family Trust presented conversion notices~~of the Company. Pursuant to the ~~Company’s transfer agent to convert their shares~~Pawlak Employment Agreement, Mr. Pawlak will act as Chief Executive Officer of the ~~Company’s Series B Preferred Stock into~~Company until the agreement is terminated in accordance with its terms, and Mr. Pawlak will be compensated as follows: (i) Mr. Pawlak will receive a base salary of $300,000 per year; (ii) Mr. Pawlak will be eligible for annual incentive bonus awards of up to 30% of Mr. Pawlak’s then-current base salary in the discretion of the compensation committee of the Board, provided that such bonus for the first year of employment shall be earned for the completion of formulation and production of a peptide topical spray (biological fungicide) that is effective in its utilization of AMPs treating plant disease, for any of the identified spectrums of crops that are targeted by the Company (the “First Milestone”), and the bonus for the second year of employment shall be earned for the receipt of regulatory approval from any of those federal agencies required by United States, such as the United States Environmental Protection Agency (the EPA), the United States Department of Agriculture (the USDA), and/or the United States Food and Drug Administration (the FDA), for the commercialization of the topical spray (the “Second Milestone”); (iii) Mr. Pawlak will initially receive 50,000 shares of Company common stock, and 950,000 shares of Company common stock which shall vest monthly for a period of 36 months (25,000 shares a month for months 1-34, and 50,000 shares a month for months 35-36); (iv) Mr. Pawlak will receive an additional equity award of 1,000,000 shares of Company common stock upon achievement of the First Milestone; (v) Mr. Pawlak will receive an additional equity award of 1,000,000 shares of Company common stock upon achievement of the Second Milestone; (vi) Mr. Pawlak will receive an additional equity award of 1,000,000 shares of Company common stock upon the commercial sale of a minimum of $10,000,000 of the topical spray; and (vii) Mr. Pawlak will receive an additional equity award of 1,000,000 shares of Company common stock upon the receipt of regulatory approval from any of those federal agencies required by the United States, such as the EPA, USDA, and/or the FDA, for the commercialization of the first seed trait based upon the Company’s patents and targeted spectrums of crops.

Effective as of January 17, 2024, the Company ~~objected~~entered into (i) indemnification agreements with each of its officers and directors, Mr. Pawlak, Ms. Miller, Dr. Jaynes and Dr. Yates (the “Indemnification Agreements”), (ii) an employment agreement with Mr. Pawlak (the “Pawlak Employment Agreement”), (iii) an employment agreement with Ms. Miller (the “Miller Employment Agreement”), (iv) a science advisor agreement with Dr. Jaynes (the “Jaynes Advisor Agreement”), and (v) a science advisor agreement with Dr. Yates (the “Yates Advisor Agreement”).

On January 17, 2024, the Company issued 50,000 shares of common stock to ~~those conversions. Shares held by LASB Family Trust may be deemed~~Mr. Pawlak in conjunction with his employment agreement. The shares were valued at $50,000.

On February 7, 2024, the Company filed suit against Justin Kimbrough and Prosperity Consultants, LLC, in the 14th Judicial District Court for Dallas County, Texas (case no. DC-24-02022), alleging fraud, conversion, unjust enrichment and other causes of action arising from the defendants’ improper receipt of shares of Company common stock under agreements which required the defendants to provide services to the Company and which services the defendants ultimately never provided. The Company is seeking monetary damages and for a constructive trust to be ~~beneficially owned by Mr. White.~~imposed on defendants’ shares of Company common stock and for them to be returned to the Company.

~~F-13~~F-18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as “anticipate,” “expects,” “intends,” “plans,” “believes,” “seeks” and “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q. Investors should carefully consider all of such risks before making an investment decision with respect to the Company’s stock. The following discussion and analysis should be read in conjunction with our financial statements and summary of selected financial data for Genvor Incorporated. Such discussion represents only the best present assessment from our Management.

Company Overview

Genvor Incorporated (the “Company”) was incorporated in Florida on September 26, 2018, as Allure Worldwide, Inc., and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from Allure Worldwide, Inc. to Genvor Incorporated.

The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the “Purchase Agreement”) with Genvor Inc., a Delaware corporation (“Genvor”) to acquire (the “Acquisition”) Genvor. On March 2, 2022, the Company and Genvor entered into a merger agreement (the “Merger Agreement”) to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the “Merger”) with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company.

On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor’s pre-merger shareholders (the “Merger Shares”), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share exchange with Genvor, and subsequently the Company’s original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition.

As a result of the Acquisition, the Company’s business plan is that of Genvor, and the Company is developing plant-based defense technology designed to help farmers achieve global food security.

The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. The Company’s technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

The Company’s headquarters is located at 13155 Noel Road, Suite 900, Dallas, Texas, 75240.

The following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q.

Plan of Operation

The United States Food and Agriculture Organization reports that annual global crop losses due to plant pathogens and viruses are now estimated to exceed $100 billion. Alarming to the FDA are the fungi “Aspergillus Flavus,” which produce Aflatoxins, a toxic and carcinogenic compound known to cause liver cancer in humans and animals. Aspergillus Flavus is also the second leading cause of “aspergillosis” in humans. Patients infected with Aspergillus flavus often have reduced or compromised immune systems.

The U.S. Food and Drug Administration estimates the annual cost of Aflatoxin contamination in the United States at approximately $500 million through two categories of loss: market rejection and animal health impacts. As a result, the United States Department of Agriculture (USDA) has imposed strict guidelines for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and harvested crops that are found to be contaminated beyond permitted testing levels must be destroyed. As a result, farmers and growers can be exposed to catastrophic economic losses. This Aflatoxin problem has created a significant opportunity for agricultural companies who can develop the technology needed to defend against Aflatoxins.

The Company’s Solution

The Company’s technology is the only known solution that it is aware of, which it believes provides broad spectrum effectiveness against Aspergillus Flavus and Aflatoxins. This technology is deliverable by both bioengineered seed trait, as well as through biopesticide application.

Dr. Jaynes, one of Genvor’s founders, has been on a 30+ year quest to find a global crop solution for defense against Aflatoxins. As a result of successful testing and collaboration between Dr. Jaynes and the United States Department of Agriculture, Agriculture Research Service (USDA-ARS), the USDA-ARS awarded Genvor with a Cooperative Research & Development Agreement in August of 2018. The stated goal of this agreement is to develop and commercialize disease resistant and nutritionally enhanced corn seed varieties using Genvor’s seed trait technology.

Seed Traits

In the United States, the adoption of crop seeds with enhanced traits has been staggering. Currently, over 90 percent of U.S. corn, cotton and soybeans are produced using seeds with enhanced traits. Trait fees for these three crops alone represent over $2 billion annually based on an average trait fee of $13 per acre on approximately 170 million acres. U.S. corn crops alone account for roughly $1.2 billion of the estimated $2 billion.

Biopesticides

Biopesticides are one of the fastest-growing crop protection market sectors, increasing at twice the compound annual growth rate of the crop protection market as a whole. Primary drivers of this growth include a rising global demand for organic foods, the trend in the reduction of chemical residues, stricter import and supermarket standards, shorter pre-harvest intervals, a push for sustainability, and the demand for additional modes of action for managing resistance. The biopesticide market in north America alone is currently estimated to be over $4.8 billion annually.

Genvor’s technology is effective with corn seed and is believed by Genvor to be effective with many known crop types, and the technology may be delivered as a topical spray in the form of a biopesticide.

Reports to Security Holders

The Company is required to file reports pursuant to Section 15(d) of the Securities Exchange Act of 1934 and is required to furnish its stockholders with annual reports containing consolidated financial statements audited by its independent registered public accounting firm and to make available quarterly reports containing unaudited condensed consolidated financial statements for each of the first three quarters of each fiscal year ending September 30^th. The Company files Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission. The Company may also file additional documents with the Commission if those documents become necessary in the course of its operations.

Available Information

All reports of the Company filed with the SEC are available free of charge through the SEC’s website at www.sec.gov. In addition, the public may read and copy materials filed by the Company at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. The public may also obtain additional information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.

Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes thereto for the three and nine months ended ~~June 30,~~December 31, 2023, and 2022, and related management discussion herein.

Our financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United States (“U.S. GAAP”).

Going Concern Qualification

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred cumulative net losses of ~~$16,657,797~~$19,070,734 from its inception to ~~June 30,~~December 31, 2023, and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through debt or future issuances of capital stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern.

For the Three Months Ended ~~June 30,~~December 31, 2023, and 2022

Revenues

We did not earn any revenues during the three months ~~ending June 30,~~ended December 31, 2023, and 2022.

Operating Loss

During the three months ~~ending June 30,~~ended December 31, 2023, and 2022, the Company had an operating loss of ~~$149,072~~$1,305,076 and ~~$645,503,~~$113,662, respectively. For the three months ~~June 30, 2022,~~December 31, 2023, the primary expenses were stock-based compensation of ~~$502,875.~~$907,100. The ~~decrease~~increase in operating loss was primarily due to ~~decreases~~increases in stock-based compensation, professional fees and other general administrative expenses during the three months ~~ending June 30,~~ended December 31, 2023, as compared to the three months ~~ending June 30,~~ended December 31, 2022.

Net Loss

The Company incurred a net loss of ~~$215,029~~$1,351,427 and ~~$687,743,~~$179,619, respectively, during the three months ended ~~June 30,~~December 31, 2023, and 2022, primarily as a result of the ~~decreasing operating loss described~~increasing operating loss described previously.

~~For the Nine Months Ended June 30, 2023, and 2022~~

~~Revenues~~

~~We did not earn any revenues during the nine months ending June 30, 2023, and 2022.~~

~~Operating Loss~~

During the nine months ending June 30, 2023, and 2022, the Company had an operating loss of $418,015 and $4,300,762, respectively. For the nine months June 30, 2022, the primary expenses were stock-based compensation of $3,712,500. The decrease in operating loss was primarily due to decreases in payroll, stock-based compensation, and other general administrative expenses during the nine months ended June 30 2022.

~~Net Loss~~

~~The Company incurred a net loss of $615,860 and $4,469,004, respectively, during the nine months ended June 30, 2023, and 2022, as a result of the decreasing operating loss described previously.~~

Liquidity and Capital Resources

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Working Capital

Cash Flow

We fund our operations with cash received from advances from officers and related parties and issuances of equity or notes payable.

Cash Flows from Operating Activities

For the ~~nine~~three months ended ~~June 30,~~December 31, 2023, as compared to the ~~nine~~three months ended ~~March~~December 31, 2022, cash used in operating expenses increased due to payments of ~~contract payroll and~~ accounts payable, as well as due to an increase in professional ~~fees and research and development expenses.~~fees.

Cash Flows from Investing Activities

For the ~~nine~~three months ended ~~June 30,~~December 31, 2023, no cashflows were provided by or used in investing activities.

Cash Flows from Financing Activities

For the ~~nine~~three months ended ~~June 30,~~December 31, 2023, cash was raised through the sale of common ~~stock and proceeds from notes payable.~~stock.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean the company’s controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a simple system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC’s rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized, and reported with the time periods specified. Our chief executive officer and chief financial officer also concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended ~~June 30,~~December 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company is not a party to any significant pending legal proceedings other than as disclosed below, and no other such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

On February 7, 2024, the Company filed suit against Justin Kimbrough and Prosperity Consultants, LLC, in the 14th Judicial District Court for Dallas County, Texas (case no. DC-24-02022), alleging fraud, conversion, unjust enrichment and other causes of action arising from the defendants’ improper receipt of shares of Company common stock under agreements which required the defendants to provide services to the Company and which services the defendants ultimately never provided. The Company is seeking monetary damages and for a constructive trust to be imposed on defendants’ shares of Company common stock and for them to be returned to the Company

ITEM 1A. RISK FACTORS.

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On ~~May 3,~~November 1, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.